Actively Recruiting
A Prospective Study to Evaluate the Implementation of Shared Decision Making Strategy for Renal Cell Cancer (RCC)
Led by St. Antonius Hospital · Updated on 2025-05-15
180
Participants Needed
1
Research Sites
13 weeks
Total Duration
On this page
Sponsors
S
St. Antonius Hospital
Lead Sponsor
M
Merck Sharp & Dohme LLC
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating the impact of two decision aids designed for patients with renal cell carcinoma (RCC) on how decisions about treatment are made and the quality of those decisions. This study focuses on both local (non-metastatic) and metastatic RCC, where treatment options vary widely depending on disease stage, tumor type, and patient preferences. The goal is to see how these decision aids affect shared decision-making between patients and healthcare professionals. The study compares usual care, where patients receive standard information, to care involving the use of two online interactive decision aids—one for local RCC and one for metastatic RCC. These aids explain treatment choices, outcomes, possible side effects, and benefits to help patients make informed decisions together with their doctors. The study is prospective and multicenter, involving groups before and after implementing the decision aids. Participants will be patients diagnosed with RCC who face treatment decisions covered by the aids. Assessments include observing shared decision-making during consultations and measuring decision quality, patient knowledge, and feelings about the decision process through questionnaires at intervals up to nine weeks after consultation. The study aims to evaluate changes in decision-making quality and how well the aids are implemented, with all data collected during and after consultations.
CONDITIONS
Brief Title
A Prospective Study to Evaluate the Implementation of Shared Decision Making Strategy for Renal Cell Cancer (RCC)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients clinically diagnosed with RCC
- Patients facing a decision which is addressed in the decision aids (T1 tumor or metastatic disease)
- Written informed consent
You will not qualify if you...
- Patients who are not able to fill in a questionnaire or undergo an interview individually
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 9 weeks after consultation
Participants with renal cell cancer are observed as they undergo usual care or use decision aids to support treatment decision-making.
1 consultation and follow-up assessments at 2 and 9 weeks after consultation
Trial Site Locations
Total: 1 location
1
St. Antonius Ziekenhuis
Nieuwegein, Utrecht, Netherlands, 3435 CM
Actively Recruiting
Research Team
C
Cato Bresser
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here